The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

27 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Electrophilic Helical Peptides That Bond Covalently, Irreversibly, and Selectively in a Protein-Protein Interaction Site.EBI
The University of Queensland
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.EBI
Abbvie
3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.EBI
University of Michigan Medical School
Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.EBI
Clermont Universit£
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.EBI
Sanford-Burnham Medical Research Institute
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.EBI
Mcgill University
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.EBI
University of Washington
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.EBI
Sanford-Burnham Medical Research Institute
Inhibition of Bfl-1 with N-aryl maleimides.EBI
Human Biomolecular Research Institute
Discovery and optimization of (2-naphthylthio)acetic acid derivative as selective Bfl-1 inhibitor.EBI
Tianjin University
Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.EBI
China Pharmaceutical University
Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy.EBI
Shandong First Medical University & Shandong Academy of Medical Sciences
Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.EBI
Yancheng Teachers University
Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.EBI
Amgen
Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1.EBI
University of California Riverside
Discovery of 3,5-Dimethyl-4-Sulfonyl-1EBI
China Pharmaceutical University
Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins.EBI
The University of Queensland
Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins.EBI
National Institute of Chemistry
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.EBI
University of Maryland
Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereofBDB
Sunshine Lake Pharma
BTK inhibitorsBDB
Merck Sharp & Dohme
Rho kinase inhibitorsBDB
Kadmon
Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agentsBDB
Duquesne University of The Holy Spirit
7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.BDB
Tokushima Research Institute
Structural basis for the highly selective inhibition of MMP-13.BDB
Aventis Pharma Deutschland
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.BDB
Bristol-Myers Squibb Pharmaceutical Research Institute
Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1).BDB
Pfizer